| http://www.w3.org/ns/prov#value | - Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve a new drug application (NDA) for LibiGel.In addition to being a major milestone for BioSante, the SPA is a significant development for the entire FSD category, said Stephen M. Simes, BioSante's president & CEO. This action by the FDA confirms FDA's posit
|
